André P. Boulet, Ph.D.
Chairman, President & CEO

Dr André Boulet has a vast experience in drug development, regulatory affairs, market access, financing and restructuration in the pharmaceutical and biotech fields. A seasoned entrepreneur, he stands out by combining his strengths in applied science, business and finance.

Within Devonian Health Group, he has raised more than $50M in private/public equity, completed phase 1 and phase 2 ulcerative colitis and Atopic Dermatitis clinical programs for the company`s flagship product Thykamine™ as well as a complete line of patented anti-aging products.

Prior to this endeavour, he was a managing partner of SIPAR’s biotech unit, a $400M private investment firm. Prior to SIPAR, Dr Boulet was partner at BioCapital III LP (« BioCapital ») (1996-2002), a Canadian biotech venture capital company.

Throughout his career, Dr Boulet acquired an international expertise in drug development, regulatory affairs and health economics within Hoechst Marion Roussel, Marion Merrell Dow Canada and Laboratoires Nordic (now Sanofi).

Dr Boulet holds a Bachelor’s Degree in Medical Biology from University of Quebec in Trois-Rivieres, a Master’s Degree in experimental medicine/immunology-immunochemistry as well as a PhD in physiology-endocrinology from Laval University in Quebec City. He also did a post-doctorate training at University of Pennsylvania (USA) in biochemistry-biophysics and a training program in Health Economics at York University (UK).

Colette Laurin, CPA, CA
Interim Chief Financial Officer

Prior to joining Devonian in 2015, Ms. Laurin was a corporate and corporate finance consultant and, for over 16 years, acquired experience in a wide range of banking sectors. She has held a number of positions at the National Bank of Canada, including Business Credit Manager, Business Center Director, and has managed to integrate and support the administrative tasks of nearly 35 bank branches, management responsibility of more than 120 employees. She has also held the position of Director of Development of the Inspection Department and Internal Audit. Prior to this, she held the position of auditor at Raymond, Chabot Martin Paré (now Raymond Chabot Grant Thornton).

Martin Moreau, M. Sc. Fin., CFA
Vice-President Finance

Mr. Moreau is a renowned leader in the field of entrepreneurship, business management and finance. He holds a Master Degree in Finance from University of Sherbrooke, as well as the CFA professional certification. Mr. Moreau started his career with CDP Capital Technologies, a venture capital firm, where he acted as Investment Analyst in the industrial and biotechnology sectors. From 2003 to 2010, he is appointed Director of Finance at Life Corp, an antimicrobial technology and infection prevention company. He is part of the team who has raised more than $80 million in new fundings, in addition of proceeding to the financial analyses of several projects, as the opening of a production facility in Asia. He subsequently (co)founded 3 seniors’ residences, these housing projects totalling more than $150 million. He also acquired Marchand Entrepreneur Électricien in 2012, and successfully developed the company to the point of making it a recognized industry leader, by means of 7 acquisitions and mergers of his competitors. In 2021, he acquired Fixations Shur-Fast, a leading North American manufacturer of precision nails and staples, in business for over 50 years. Mr. Moreau serves on various boards of directors, business development groups and investment committees.

Dr Daniel Bouthillier, PhD
Vice-President, Research

Daniel Bouthillier has over 30 years of experience in research administration. He is presently Vice-President Research at Devonian Health Group Inc. Previously, he was a co-founder of Kaneq Pharma and Kaneq Bioscience. Mr. Bouthillier also occupied various positions at Merck&Co where he was Executive Director of Research Administration and Planning for various research sites in North America. He was also Executive Director for Merck Global Facilities Management with responsibilities for Canada, US, South America, and Asia. In previous positions, Mr. Bouthillier was Senior Scientist and Administrator at the Clinical Research Institute of Montreal and also Head of Biochemistry at l’Hôtel-Dieu de Sorel and at Fleury Hospital in Montreal. He sits on many evaluation committees and boards such as Centre québécois d’innovation en biotechnologie (CQIB), and Kanyr Pharma. Mr. Bouthillier received his Ph.D. in Clinical Sciences from the Université de Montréal and holds a certification in Clinical Biochemistry. He also completed an MBA at l’École des Hautes Études Commerciales in Montreal.

Nathalie Boucher, Ph.D.
Director, Research and Intellectual Property

Nathalie Boucher holds a bachelor’s degree in biochemistry, a master’s degree in biophysics, and a Ph.D. in environmental science (with a specialization in toxicology). She has many years of experience in both private and university research centers and stands out for her expertise in plant physiology, plant cell extraction, and enzyme stabilization. She has also contributed to the writing of numerous patents and scientific articles.